| Cadence Pharmaceuticals is recently down 70c to $8.85. Cadence Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act goal date for its Priority Review of the New Drug Application for intravenous acetaminophen by three months. The extended PDUFA goal date is February 12, 2010. CADX December option implied volatility of 67 is below a level of at 128 from November 6, February is at 120, May is at 115; verses its 3-month average of 111 according to Track Data. :theflyonthewall.com |
Subscribe for More Information